Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100716 | 0.88 | CYP1A2 (0.61) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL9360017 | 0.86 | CYP1A2 (0.69) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL11313816 | 0.86 | ALDH1A1 (0.75) | CYP1A2CYP2C19HPGDCYP3A4CYP2C9 | |
| SCHEMBL2601961 | 0.86 | CYP1A2 (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL1333620 | 0.86 | CYP1A2 (0.81) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL15100715 | 0.85 | CYP1A2 (0.58) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL6654012 | 0.85 | SLC22A6 (0.59) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL1545793 | 0.83 | SLC22A6 (0.83) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL25688103 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2C19HPGDCYP2D6CYP3A4 | |
| SCHEMBL31406172 | 0.82 | CA12 (0.71) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192908-A1 | BIOMASS-DERIVED PHOTOINITIATORS | BOWLING GREEN STATE UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| CN-114409564-A | Compound containing trityl structure and application thereof | 广州同隽医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1539749-A4 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| US-7105533-B2 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1539749-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024074-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | GRM5, GRIK5, GRM1 | CYP1A2 4282/4885CYP2C19 2502/4885HPGD 2806/4885 |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | CYP1A2 308/4885CYP2C19 411/4885HPGD 369/4885 |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | CYP1A2 308/4885CYP2C19 411/4885HPGD 369/4885 |
| US-20230192908-A1 | BIOMASS-DERIVED PHOTOINITIATORS | BLVRB, CYP1B1, GLB1 | CYP1A2 39/4885CYP2C19 148/4885HPGD 245/4885 |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | CYP1A2 75/4885CYP2C19 206/4885HPGD 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.